lactic acid has been researched along with Intraocular Pressure in 26 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of a biodegradable microfilm with sustained release of prednisolone acetate (PA) on postoperative wound healing after experimental glaucoma filtration surgery (GFS)." | 7.77 | Evaluation of sustained release of PLC-loaded prednisolone acetate microfilm on postoperative inflammation in an experimental model of glaucoma filtration surgery. ( Ang, M; Foo, S; Venkatraman, SS; Wong, TT; Yan, P; Zhen, M, 2011) |
| "Ethacrynic acid (ECA) is a potential glaucoma drug that can reduce intraocular pressure." | 7.72 | Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. ( Challa, P; Epstein, DL; Wang, Y; Yuan, F, 2004) |
| "Dorzolamide was ion paired with sodium dodecyl sulfate (SDS) and sodium oleate (SO) with 0." | 5.43 | Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits. ( Fridley, C; Fu, J; Gedam, M; Hanes, J; Hu, Q; Liu, W; Liu, Y; Pitha, I; Quigley, HA; Sun, F, 2016) |
| "Poor drug penetration and rapid clearance after topical instillation of a drug formulation into the eyes are the major causes for the lower ocular bioavailability from conventional eye drops." | 5.40 | Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits. ( Ahmad, FJ; Anwar, M; Garg, V; Jain, GK; Khar, RK; Talegaonkar, S; Warsi, MH, 2014) |
| "Dorzolamide eye drops are widely prescribed to reduce intraocular pressure (IOP) in the treatment of ocular hypertension and glaucoma." | 3.85 | Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles. ( Choy, YB; Huh, BK; Kim, SN; Kim, YK; Lee, SH; Park, CG; Park, KH; Park, MA; Won, H, 2017) |
| " We designed and developed a novel drug delivery system (DDS) comprising cyclosporine A (CsA) and poly(lactic-co-glycolic acid) (PLGA) based on a glaucoma drainage device (GDD) that can continuously release CsA to prevent postoperative fibrosis following glaucoma surgery." | 3.83 | Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis. ( Dai, Z; Hong, J; Liu, X; Sun, J; Sun, X; Yu, X, 2016) |
| "Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP)." | 3.79 | Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. ( Bucolo, C; Carbone, C; Drago, F; Musumeci, T; Pignatello, R; Puglisi, G, 2013) |
| "To evaluate the effect of a biodegradable microfilm with sustained release of prednisolone acetate (PA) on postoperative wound healing after experimental glaucoma filtration surgery (GFS)." | 3.77 | Evaluation of sustained release of PLC-loaded prednisolone acetate microfilm on postoperative inflammation in an experimental model of glaucoma filtration surgery. ( Ang, M; Foo, S; Venkatraman, SS; Wong, TT; Yan, P; Zhen, M, 2011) |
| "Ethacrynic acid (ECA) is a potential glaucoma drug that can reduce intraocular pressure." | 3.72 | Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. ( Challa, P; Epstein, DL; Wang, Y; Yuan, F, 2004) |
| "Intraocular pressure was measured using applanation tonometry." | 2.67 | Correlates of acute exercise-induced ocular hypotension. ( Harris, A; Malinovsky, V; Martin, B, 1994) |
| "Dorzolamide was ion paired with sodium dodecyl sulfate (SDS) and sodium oleate (SO) with 0." | 1.43 | Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits. ( Fridley, C; Fu, J; Gedam, M; Hanes, J; Hu, Q; Liu, W; Liu, Y; Pitha, I; Quigley, HA; Sun, F, 2016) |
| "Poor drug penetration and rapid clearance after topical instillation of a drug formulation into the eyes are the major causes for the lower ocular bioavailability from conventional eye drops." | 1.40 | Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits. ( Ahmad, FJ; Anwar, M; Garg, V; Jain, GK; Khar, RK; Talegaonkar, S; Warsi, MH, 2014) |
| " Our work demonstrated that this new platform is capable of enhancing drug bioavailability and sustaining effective IOP reduction over an extended period of time." | 1.38 | Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ( Holden, CA; Kadam, RS; Kompella, UB; Tyagi, P; Yang, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 15 (57.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vohra, R | 1 |
| Dalgaard, LM | 1 |
| Vibaek, J | 1 |
| Langbøl, MA | 1 |
| Bergersen, LH | 1 |
| Olsen, NV | 1 |
| Hassel, B | 1 |
| Chaudhry, FA | 1 |
| Kolko, M | 1 |
| Rodríguez-Agirretxe, I | 1 |
| Vega, SC | 1 |
| Rezola, R | 1 |
| Vecino, E | 1 |
| Mendicute, J | 1 |
| Suarez-Cortes, T | 1 |
| Acera, A | 1 |
| Pattarini, JM | 1 |
| Blue, RS | 1 |
| Aikins, LT | 1 |
| Law, J | 1 |
| Walshe, AD | 1 |
| Garbino, A | 1 |
| Turney, MW | 1 |
| Clark, JB | 1 |
| Warsi, MH | 1 |
| Anwar, M | 1 |
| Garg, V | 1 |
| Jain, GK | 1 |
| Talegaonkar, S | 1 |
| Ahmad, FJ | 1 |
| Khar, RK | 1 |
| Dai, Z | 1 |
| Yu, X | 1 |
| Hong, J | 1 |
| Liu, X | 1 |
| Sun, J | 2 |
| Sun, X | 1 |
| Fu, J | 1 |
| Sun, F | 1 |
| Liu, W | 1 |
| Liu, Y | 1 |
| Gedam, M | 1 |
| Hu, Q | 1 |
| Fridley, C | 1 |
| Quigley, HA | 1 |
| Hanes, J | 1 |
| Pitha, I | 1 |
| Park, CG | 1 |
| Kim, YK | 1 |
| Kim, SN | 1 |
| Lee, SH | 1 |
| Huh, BK | 1 |
| Park, MA | 1 |
| Won, H | 1 |
| Park, KH | 1 |
| Choy, YB | 1 |
| Salama, HA | 1 |
| Ghorab, M | 1 |
| Mahmoud, AA | 1 |
| Abdel Hady, M | 1 |
| Cui, LJ | 1 |
| Sun, NX | 1 |
| Li, XH | 1 |
| Huang, J | 1 |
| Yang, JG | 1 |
| Paganelli, F | 1 |
| Cardillo, JA | 1 |
| Melo, LA | 1 |
| Lucena, DR | 1 |
| Silva, AA | 1 |
| Oliveira, AG | 1 |
| Höfling-Lima, AL | 1 |
| Nguyen, QD | 1 |
| Kuppermann, BD | 2 |
| Belfort, R | 1 |
| Grozdanic, SD | 1 |
| Lazic, T | 1 |
| Kuehn, MH | 1 |
| Harper, MM | 1 |
| Kardon, RH | 1 |
| Kwon, YH | 1 |
| Lavik, EB | 1 |
| Sakaguchi, DS | 1 |
| Checa-Casalengua, P | 1 |
| Jiang, C | 1 |
| Bravo-Osuna, I | 1 |
| Tucker, BA | 1 |
| Molina-Martínez, IT | 1 |
| Young, MJ | 1 |
| Herrero-Vanrell, R | 1 |
| Kruschewsky, Lde S | 1 |
| Novais, T | 1 |
| Daltro, C | 1 |
| Castelo Branco, B | 1 |
| Lessa, M | 1 |
| Kruschewsky, MB | 1 |
| de Mello-Filho, FV | 1 |
| Ang, M | 1 |
| Yan, P | 1 |
| Zhen, M | 1 |
| Foo, S | 1 |
| Venkatraman, SS | 1 |
| Wong, TT | 1 |
| Doganay, S | 1 |
| Cankaya, C | 1 |
| Alkan, A | 1 |
| Yang, H | 1 |
| Tyagi, P | 1 |
| Kadam, RS | 1 |
| Holden, CA | 1 |
| Kompella, UB | 1 |
| Musumeci, T | 1 |
| Bucolo, C | 1 |
| Carbone, C | 1 |
| Pignatello, R | 1 |
| Drago, F | 1 |
| Puglisi, G | 1 |
| Xie, L | 1 |
| Yao, Z | 1 |
| Wang, Y | 1 |
| Challa, P | 1 |
| Epstein, DL | 1 |
| Yuan, F | 1 |
| Blumenkranz, MS | 1 |
| Haller, JA | 1 |
| Williams, GA | 1 |
| Weinberg, DV | 1 |
| Chou, C | 1 |
| Whitcup, SM | 1 |
| Yamashita, T | 1 |
| Sakamoto, T | 1 |
| Yamakiri, K | 1 |
| Miura, M | 1 |
| Enaida, H | 1 |
| Ueno, A | 1 |
| Atsumi, I | 1 |
| Matsuhisa, K | 1 |
| Sakamoto, Y | 1 |
| Kida, T | 1 |
| Ishibashi, T | 1 |
| Harris, A | 1 |
| Malinovsky, V | 1 |
| Martin, B | 1 |
| Tan, DT | 2 |
| Chee, SP | 2 |
| Lim, L | 2 |
| Lim, AS | 1 |
| Lu, DW | 1 |
| Chang, CJ | 1 |
| Chiang, CH | 1 |
| Yeh, MK | 1 |
| Chou, PI | 1 |
| Theng, J | 1 |
| Van Ede, M | 1 |
| Ashkenazi, I | 1 |
| Melamed, S | 1 |
| Blumenthal, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery[NCT00431028] | Phase 1/Phase 2 | 140 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to Terminated) | ||
| Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome[NCT00035906] | Phase 2 | 315 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma[NCT01471054] | Phase 2 | 6 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Could not enroll enough patients.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Increase or decrease in central subfield retinal thickness in microns based on spectral-domain optical coherence tomography measurement (NCT01471054)
Timeframe: At 12 months
| Intervention | micron (Median) |
|---|---|
| Ozurdex | -120 |
| Bevacizumab | -4 |
Development of visually-significant lens opacity based on judgement of examining physician. (NCT01471054)
Timeframe: At 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ozurdex | 3 |
| Bevacizumab | 0 |
Intraocular pressure more than 21 mm Hg as measured with applanation tonometry. (NCT01471054)
Timeframe: At 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ozurdex | 3 |
| Bevacizumab | 0 |
Development of rhegmatogenous retinal detachment in the study eye. (NCT01471054)
Timeframe: At 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ozurdex | 0 |
| Bevacizumab | 0 |
Development of hemorrhage in the vitreous cavity detectable with slit lamp examination or dilated funduscopy. (NCT01471054)
Timeframe: At 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ozurdex | 0 |
| Bevacizumab | 0 |
The number of participants that developed 2 or more lines of visual acuity improvement in the study eye. Visual acuity was measured with Snellen eye chart placed 10 feet away from the patient. (NCT01471054)
Timeframe: At 12 months
| Intervention | participants (Number) |
|---|---|
| Ozurdex | 2 |
| Bevacizumab | 0 |
1 review available for lactic acid and Intraocular Pressure
| Article | Year |
|---|---|
Flat spin and negative Gz in high-altitude free fall: pathophysiology, prevention, and treatment.
Topics: Altitude; Arrhythmias, Cardiac; Blood Glucose; Brain Edema; Cerebrovascular Circulation; Confusion; | 2013 |
6 trials available for lactic acid and Intraocular Pressure
| Article | Year |
|---|---|
A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery.
Topics: Aged; Anterior Chamber; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Connective T | 2009 |
Fractured orbital wall reconstruction with an auricular cartilage graft or absorbable polyacid copolymer.
Topics: Absorbable Implants; Adult; Biocompatible Materials; Diplopia; Ear Cartilage; Ectropion; Enophthalmo | 2011 |
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biocompatible Materials; Dexamethasone; Double-Blind Met | 2007 |
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biocompatible Materials; Dexamethasone; Double-Blind Met | 2007 |
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biocompatible Materials; Dexamethasone; Double-Blind Met | 2007 |
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biocompatible Materials; Dexamethasone; Double-Blind Met | 2007 |
Correlates of acute exercise-induced ocular hypotension.
Topics: Betaxolol; Blood Pressure; Exercise; Female; Heart Rate; Humans; Intraocular Pressure; Lactates; Lac | 1994 |
Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation.
Topics: Aged; Anterior Chamber; Anti-Inflammatory Agents; Biocompatible Materials; Cataract Extraction; Cell | 1999 |
Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye.
Topics: Aged; Anterior Chamber; Biocompatible Materials; Cataract Extraction; Dexamethasone; Double-Blind Me | 2001 |
19 other studies available for lactic acid and Intraocular Pressure
| Article | Year |
|---|---|
Potential metabolic markers in glaucoma and their regulation in response to hypoxia.
Topics: Aged; Amino Acids; Biomarkers; Blood Glucose; Chromatography, High Pressure Liquid; Female; Glaucoma | 2019 |
The PLGA implant as an antimitotic delivery system after experimental trabeculectomy.
Topics: Animals; Antimitotic Agents; Coated Materials, Biocompatible; Conjunctiva; Disease Models, Animal; D | 2013 |
Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits.
Topics: Animals; Carbonic Anhydrase Inhibitors; Glaucoma; Intraocular Pressure; Lactic Acid; Microscopy, Ele | 2014 |
Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis.
Topics: Animals; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Cyclosporine; Drainag | 2016 |
Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits.
Topics: Animals; Antihypertensive Agents; Carbonic Anhydrase Inhibitors; Ethylamines; Female; Glaucoma; Intr | 2016 |
Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles.
Topics: Adhesives; Administration, Ophthalmic; Administration, Topical; Animals; Carbonic Anhydrase Inhibito | 2017 |
PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma.
Topics: Animals; Conjunctiva; Drug Carriers; Drug Delivery Systems; Drug Liberation; Glaucoma; Intraocular P | 2017 |
Subconjunctival sustained release 5-fluorouracil for glaucoma filtration surgery.
Topics: Animals; Antimetabolites; Aqueous Humor; Chromatography, High Pressure Liquid; Conjunctiva; Delayed- | 2008 |
Exogenous modulation of intrinsic optic nerve neuroprotective activity.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Survival; Ciliary Neurotrophic Factor; Disease Mode | 2010 |
Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure.
Topics: Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Drug Carriers; Drug Combinations; D | 2011 |
Evaluation of sustained release of PLC-loaded prednisolone acetate microfilm on postoperative inflammation in an experimental model of glaucoma filtration surgery.
Topics: Animals; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Endophthalmitis; Female | 2011 |
Evaluation of corpus geniculatum laterale and vitreous fluid by magnetic resonance spectroscopy in patients with glaucoma; a preliminary study.
Topics: Aged; Apoptosis; Aspartic Acid; Choline; Creatine; Female; Geniculate Bodies; Glaucoma, Open-Angle; | 2012 |
Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration.
Topics: Administration, Topical; Animals; Antihypertensive Agents; Delayed-Action Preparations; Dendrimers; | 2012 |
Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits.
Topics: Administration, Ophthalmic; Animals; Delayed-Action Preparations; Drug Carriers; Drug Compounding; D | 2013 |
Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes.
Topics: Animals; Aqueous Humor; Biocompatible Materials; Cataract; Drug Delivery Systems; Drug Implants; Fib | 2003 |
Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment.
Topics: Absorption; Animals; Delayed-Action Preparations; Diffusion; Drug Evaluation, Preclinical; Ethacryni | 2004 |
Polylactic acid for visualizing the vitreous body during vitrectomy.
Topics: Animals; Anterior Eye Segment; Contrast Media; Electroretinography; Injections; Intraocular Pressure | 2007 |
Wound modulation after trabeculectomy by different formulations of antimetabolites in rabbits.
Topics: Animals; Antimetabolites; Biocompatible Materials; Conjunctiva; Dose-Response Relationship, Drug; Dr | 2000 |
The effect of continuous strenuous exercise on intraocular pressure.
Topics: Adult; Blood Physiological Phenomena; Humans; Hydrogen-Ion Concentration; Intraocular Pressure; Lact | 1992 |